CAR Macrophages in Brain Tumor Immunotherapy: Molecular Engineering Strategies and Emerging Frontiers

The CNS is partly shielded from immune attack, which allows tumor cells to escape many conventional therapies, including CAR-T. CAR-M therapy is an alternative approach that exploits the ability of myeloid cells to enter the CNS, engulf tumor cells, and shift the immunosuppressive microenvironment. This review focuses on molecular engineering principles for next-generation CAR-M constructs, including signaling domain selection, CD47-SIRPα checkpoint strategies, and gene delivery platforms for myeloid cells. We also discuss CNS-specific delivery routes and the multi-layered anti-tumor mechanisms of CAR-M, such as phagocytosis, TME remodeling, and innate–adaptive immune bridging. Combination strategies with checkpoint inhibitors, oncolytic viruses, and chemotherapy are analyzed, together with emerging approaches like SIGLEC9-based chimeric switch receptors, enucleated MSC-mediated in situ CAR-M generation, and circRNA-based CAR expression. We then address CNS-specific safety considerations and translational challenges.

Authors

Institutions

Publication Details

Journal
Biomolecules
Published
2026-11-12
DOI
https://doi.org/10.3390/biom16111650
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CAR Macrophages in Brain Tumor Immunotherapy: Molecular Engineering Strategies and Emerging Frontiers

Yixuan Ran, Meng Li, Yufei Li, Qiang Hao et al.
Biomolecules
CAR-T cell therapy research
article

CAR Macrophages in Brain Tumor Immunotherapy: Molecular Engineering Strategies and Emerging Frontiers

Yixuan Ran, Meng Li, Yufei Li, Qiang Hao, Huihui Ou, Jingyi Yun, Jintao Gu, Mo Li, Yuchen Han
article en

Abstract

The CNS is partly shielded from immune attack, which allows tumor cells to escape many conventional therapies, including CAR-T. CAR-M therapy is an alternative approach that exploits the ability of myeloid cells to enter the CNS, engulf tumor cells, and shift the immunosuppressive microenvironment. This review focuses on molecular engineering principles for next-generation CAR-M constructs, including signaling domain selection, CD47-SIRPα checkpoint strategies, and gene delivery platforms for myeloid cells. We also discuss CNS-specific delivery routes and the multi-layered anti-tumor mechanisms of CAR-M, such as phagocytosis, TME remodeling, and innate–adaptive immune bridging. Combination strategies with checkpoint inhibitors, oncolytic viruses, and chemotherapy are analyzed, together with emerging approaches like SIGLEC9-based chimeric switch receptors, enucleated MSC-mediated in situ CAR-M generation, and circRNA-based CAR expression. We then address CNS-specific safety considerations and translational challenges.

BiomoleculesVol. 16(11)
Northwest University (CN), Xijing Hospital (CN), Air Force Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon